A review of etripamil: A new paradigm for treating paroxysmal supraventricular tachycardia for an informed, shared decision.

Overview

Paroxysmal supraventricular tachycardia (PSVT) is associated with significant morbidity and affects 1 in 300 people. This article reviews the contemporary management of PSVT and the potential role of intranasal etripamil, a recently Food and Drug Administration-approved intranasal calcium channel blocker that can be used to safely and effectively terminate PSVT in an outpatient setting and avoid urgent medical attention. When combined with the use of wearable devices, this paradigm shift of enabling patients to self-treat PSVT with an on-demand therapy provides another option to be considered in shared decision making for PSVT management.